Abstract

   Fluconazole is a subclass of triazole antifungal  agents, is available as oral tablets, powder or for oral suspension, and as a sterile solution for intravenous administration. Fluconazole is designated chemically as 2,4-difluoro-α,α¹-bis benzyl alcohol in the form of white crystalline solid which is slightly soluble in water and saline. Fluconazole oral suspension contains 350 mg or 1400 mg contains sucrose, citric acid anhydrous, sodium benzoate, sodium citrate, colloidal, silicon dioxide, titanium dioxide, xanthan gum, and natural orange flavor. After reconstitution with 24 ml of distilled water or purified water each ml of reconstituted suspension contains 10 mg or 40 mg of fluconazole. Animals are divided into 4 groups. The rats of group A were taken as control group. In group B rats are kept nil per orally at 12 hours prior to induction of septic shock produce by Candida albicans s. Group C animals are administrated with fluconazole at doses of 3mg/kg, 10mg/kg and 30mg/kg after the septic shock produce by Candida albicans s. Since fluconazole at a higher dose had clearly shown to decrease tissue injury. We decided to keep fluconazole dose as constant and vitamin E would be administered in dose of 10mg/100gm of body weight in group D. Both the drugs are administrated after inducing septic shock. After the study, animals sacrificed and lungs obtained within 8 hours of septic shock. Lungs are taken out from sacrificed animals and then fixed with paraffin and then sectioned and stained by eosin and haemotoxylin. With the help of cardiac puncture blood samples were taken to estimate the infectious markers. Study of CBC and CRP was done. The levels were estimated and compared with control and correlated with histologic findings. The lung histology is determined by mucosal thickening and inflammatory cells. All these results were in favor of group D fluconazole along with vitamin E that shows significant results in all parameters. There was significant correlation between control and fluconazole along with vitamin E treated group because vitamin E reduces the histopathological changes in lungs parenchyma. It is concluded from the study that vitamin E when treated with combination of fluconazole it decreases the lung tissue injury and oxidative stress.

Results: The present study reveals that the distorting effects of Candida albicans s on lung mucosa and establish improved effects of fluconazole decrease the elevated levels of TLC, Lymphocytes, CRP, neutrophils and attenuate the lung injury.

Conclusion: From this study it is concluded that the fluconazole attenuated lung injury and the biochemical and histopathological changes were more improved by addition of vitamin E. Because it acts as potent antioxidant agent.

Keywords: Lungs Histology; Fluconazole; Vitamin E; Septic Shock

References

1. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)". Journal of the American Medical Association 8 (2016): 801-810.
2. Jui Jonathan. In Tintinalli, Judith E.; Stapczynski, J. Stephan; Ma, O. John; Cline, David M.; et al. Tintinalli's Emergency Medicine: A Comprehensive Study Guide (7th ed.). New York: McGraw-Hill. Ch. 146: Septic Shock" (2012): 1003-1014.
3. Kumar V., et al. “Robbins Basic Pathology (8th ed.)”. Saunders, Elsevier (2017): 102-103.
4. Melis M., et al. “Bowel necrosis associated with early jejunal tube feeding: A complication of postoperative enteral nutrition". Archives of Surgery7 (2006): 701-704.
5. Jun-Gyo Gwon., et al. “Enteral nutrition associated non-occlusive bowel ischemia". Journal of Korean Surgical Society 3 (2012): 171-174.
6. Angus Derek C and van der Poll Tom. "Severe Sepsis and Septic Shock". New England Journal of Medicine9 (2013): 840-851.
7. Martin GS. "Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes". Expert Review of Anti-infective Therapy 6 (2012): 701-706.
8. Dellinger RP., et al. “Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock”. Critical Care Medicine2 (2013): 580-637.
9. Maton A., et al. “Human Biology and Health”. Prentice Hall, Englewood Cliffs. New Jersey (2010): 108-118.
10. Tortora J., et al. “Principles of anatomy and physiology, 13th edition”. Harper and Row, New Jersey (2012): 570-572.
11. Von Euler Liljestrand US. “Observations on the pulmonary arterial blood pressure in the rat”. Acta Physiologica Scandinavica 12 (1946): 301-320.
12. West JB. “Respiratory physiology”. The essentials, Baltimore: Williams and Wilkins (1985): 21-30, 84-84, 98-101.
13. Sullivan LC and Orgeig S. “Lung Development and Respiratory Distress Syndrome”. American Journal of Physiology 3 (2010): 770-778.
14. "Fluconazole (Diflucan): Drug Safety Communication - FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy". FDA (2016).
15. "WHO Model List of Essential Medicines". World Health Organization (2013).
16. Bennett JE. “Antifungal Agents”. Chabner B.A. Knollmann B.C, Goodman and Gilman's The Pharmacological Basis of Therapeutics, In L.L. Brunton 12e (2012).
17. Fluconazole monograph. The American Society of Health-System Pharmacists (2014).
18. Pfizer Australia Pvt Ltd. Diflucan (Australian Approved Product Information). West Ryde (NSW): Pfizer Australia (2004).
19. Tortora Gerald J. “An Introduction of Microbiology”. San Francisco. CA Pearson Benjamin Cummings (2010): 758.
20. Mukherjee PK., et al. “Mycobiota in gastrointestinal diseases". Nature Reviews Gastroenterology and Hepatology 2 (2014): 77-87.
21. Ohama T., et al. “Non-universal decoding of the leucine codon CUG in several Candida species". Nucleic Acids Research 17 (1993): 1039-4045.
22. Andrzej AE and Ostell J. "The Alternative Yeast Nuclear Code". The Genetic Codes. Bethesda, Maryland, U.S.A.: National Center for Biotechnology Information (NCBI). 31.3 (2010): 937-947.
23. Sydnor Emily. "Hospital Epidemiology and Infection Control in Acute-Care Settings". Clinical Microbiology Reviews 24 (2011): 141-173.
24. Weinberger M. "Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality". Journal of Hospital Infections 61 (2016): 146-154.
25. "Vitamin E — Health Professional Fact Sheet". Office of Dietary Supplements, US National Institutes of Health (2016).
26. Angelo Azzi A and Stocker A. “Vitamin non oxidative role”. 39.31 (2000): 231-255.
27. Story M and Stang J. "Nutritional needs of adolescents”. Guidelines for adolescent nutrition services. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota. (2005): 21-34.
28. Wang X., et al. “Vitamin E and its function in membranes”. Progress in Lipid Research4 (1999): 309-360.
29. Gropper S and Smith JL. “Fat soluble Vitamins: Advanced human nutrition”. Jones and amp: Barlett Publishers. Burlington (2013): 284.
30. Traber MG. “Vitamin E Inadequacy in Humans: Causes and Consequences”. Advances in Nutrition 5 (2014): 503-514.
31. Norhona-Blob N., et al. “Reduces mortality associated with sepsis in rats”. Journal of Pharmacology and Experimental Therapeutics 267 (1993): 664-666.
32. Tariq M. “Fluconazole attenuates lung injury and mortality in a rat peritonitis model”. Intensive Care Medicine (2003) 29:2043-2049.
33. MUSTAFA N., et al. “İnsan-COVID-19'da Pandemik SARS coronavirus-2 Enfeksiyonlari”. İstanbul Gelişim Üniversitesi Sağlik Bilimleri Dergisi 10 (2020): 77- 93.
34. "Outbred rats - Sprague Dawley Outbred Rat". Harlan Laboratories - Animal Research Laboratory - Contract Research Services (2012).
35. Kostiala I. “C-reactive protein response induced by fungal infections”. Journal of Infection3 (1984): 212-220.
36. Hpoke A., et al. “Neutrophil Attack Triggers Extracellular Trap-Dependent Candida Cell Wall Remodeling and Altered Immune Recognition”. Plos Pathogens (2016).
37. Ashman RB. “Cell-mediated immune responses correlate directly with susceptibility and resistance to infection”. Immunology and Cell Biology 68 (1990): 15-20.
38. Kathiravan MK., et al. “The biology and chemistry of antifungal agents: a review”. Bioorganic and Medicinal Chemistry 19 (2012): 5678-5698.
39. Fakruddin M., et al. “Antimicrobial and antioxidant activities of Saccharomyces cerevisiae IFST062013, a potential probiotic”. BMC Complementary and Alternative Medicine 17 (2017): 64.
40. Timonen TT and Koistinen P. “C-reactive protein for detection and follow-up of bacterial and fungal infections in severely neutropenic patients with acute leukaemia”. European Journal of Cancer and Clinical Oncology5 (1985): 557-562.
41. Mustafa N., et al. “Collaborative learning aspect for training hip and knee joint anatomy”. Journal of Rheumatic Diseases and Treatment 1 (2020): 13-16.
42. Tariq M., et al. “Fluconazole attenuates lung injury and mortality in a rat peritonitis model”. Intensive Care Medicine 29 (2003): 2043-2049.
43. Morita N., et al. “Vitamin E attenuates acute lung injury in sheep with burn and smoke inhalation injury”. Redox Report 2 (2006): 61-70.
44. Barbara Y., et al. “Wheatear’s Functional Histology”. Churchill Livingstone (2013): 207-208.
45. Peckham M. “Histology at a Glance”. Wiley-Blackwell. Churchill Livingstone (2011): 67.

Citation

Citation: Nasir Mustafa., et al. “The Effect on Histo-morphology of Lungs in Fluconazole and Vitamin E Treated Sprague Dawley Albino Rats with Septic Shock". Acta Scientific Neurology 3.12 (2020): 13-22.

Copyright

Copyright: © 2020 Nasir Mustafa., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.